Alovudine Medivir.
Medivir is developing alovudine, an anti-HIV compound for the potential treatment of drug-resistant HIV infection. A phase IIa trial involving patients with multiresistant HIV was initiated in October 2001 and by July 2002, the trial had been completed.
Rusconi
Stefano
S
Istituto di Malattie Infettive e Tropicali Università degli Studi Ospedale Luigi Sacco via GB Grassi 74, 20157 Milano, Italy. rusconi@mailserver.unimi.it
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D015658:HIV Infections / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors*; D015497:HIV-1; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D013329:Structure-Activity Relationship
D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase; C002854:alovudine